linjc16/ctgov huggingface dataset:
Predictors of Driving Performance and Successful Mobility - Rehabilitation in Patients With Medical Eye Condition

Study Overview
=================
Brief Summary
-----------------
There are two diseases in particular that may have serious consequences for driving and mobility due to their potentially severe impact on visual function: glaucoma and diabetic neuropathy. In this project we will develop predictive models of driving for these patients and will train them to use low-vision aids to improve driving mobility. We will determine how best to train patients with hemianopic field loss due to cerebral vascular accidents and identify predictors of long-term success in the use of low-vision aids.

Detailed Description
-----------------
There are two diseases in particular that may have serious consequences for driving and mobility due to their potentially severe impact on visual function: glaucoma and diabetic neuropathy. Both these diseases can potentially result in significant peripheral visual field loss, sometimes coupled with decreased visual acuity. We have previously demonstrated that each of these visual losses alone can have significant impact on driving and mobility performance. In this project we will develop predictive models of driving for these patients and apply our extensive expertise in training patients to use low-vision aids to improve driving mobility. A second question that will be addressed is how to best train scanning patients with hemianopic field loss due to cerebral vascular accidents. We propose to configure the prisms in a bioptic form similar to previously used for amorphic lenses in RP and for bioptic telescopes for patients in macular disease. The third problem that will be addressed is the identification of predictors of long-term success in the use of low-vision aids.

Official Title
-----------------
Predictors of Driving Performance and Successful Mobility - Rehabilitation in Patients With Medical Eye Condition

Conditions
-----------------
Low Vision

Intervention / Treatment
-----------------
* Procedure: Low vision


Participation Criteria
=================
Eligibility Criteria
-----------------
Eye impairment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Low vision|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low vision, Driving rehabilitation
Noninvasive Hemoglobin Repeatability and Reproducibility in a Blood Donation Setting

Study Overview
=================
Brief Summary
-----------------
The primary objective of this clinical investigation is to report on the repeatability and reproducibility of SpHb measurements from Rad-67 devices and DCI Mini sensors used to screen prospective blood donors at a donation center.

Official Title
-----------------
Noninvasive Hemoglobin Spot Check Repeatability and Reproducibility in a Blood Donation Setting

Conditions
-----------------
Healthy, Anemia

Intervention / Treatment
-----------------
* Device: Rad-67 Pulse oximeter & DCI Mini sensor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Weight at least 110 pounds Subjects with the intention of being screened for eligibility to donate blood The subject has given written informed consent to participate in the study Exclusion Criteria: Subjects with skin abnormalities at the planned application sites that may interfere with sensor application, per directions-for-use (DFU) or trans-illumination of the site, such as burns, scar tissue, infections, abnormalities, etc. Subjects unwilling to remove nail polish or acrylic nails Subjects with blood cancers such as leukemia Subjects with hemoglobin disorders such as sickle-cell anemia and thalassemia or with known history of infectious diseases such as HIV/AIDS, syphilis, hepatitis, etc. Subjects with self-disclosed/known pregnancy at the time of enrollment Subjects deemed not suitable for the study at the discretion of the investigator Subjects unlikely to be able to refrain from excessive motion during data collection. Excessive motion includes postural changes, making hand gestures, involuntary muscular movements, etc.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test subjects<br>All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin. | Device: Rad-67 Pulse oximeter & DCI Mini sensor<br>* Noninvasive pulse oximeter that measures hemoglobin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coefficient of Variation of Rad-67 | Coefficient of variation will be computed using Repeatability and Reproducibility variance. | Approximately 90 minutes per subject |
Accuracy of Cough Detection in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
Cough is part of the defense mechanism to protect the lung from foreign particles and remove secretions from the airways. However, at times it becomes a bothersome, annoying symptom that interferes with the quality of life, sleep pattern and exercise tolerance of the patient. People with respiratory infection, asthmatic patients and CF patients suffer from a multitude of pathologies of airways and are often inflicted with chronic cough. Treatment of cough in these patients consists of many types of expectorants, cough suppressors, secretion modifiers, inhaled bronchodilators etc. In addition, chest physical therapy (PT) is often prescribed as part of the treatment regime. The primary objective of the study is to evaluate the efficacy and validity of novel cough counting device based on the WIM Technology.

Official Title
-----------------
Use of Objective Cough Counting Device to Assess the Accuracy of Cough Detection in Healthy Adults Simulating Cough in Different Postures, Mobility and Environmental Conditions

Conditions
-----------------
Cough

Intervention / Treatment
-----------------
* Device: pulmonary sounds analyzer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient signed informed consent Patients above 21 years old No medical history Exclusion Criteria: Skin lesions precluding attachment of sensors Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br> | Device: pulmonary sounds analyzer<br>* Cough counting device based on the WIM Technology<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate cough detection and counting technology (ACCA) for adult people in different recording conditions |  | within 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cough, Wheeze Rate, Respiratory Function Tests
Elective Neurectomy During Inguinal Hernia Repair

Study Overview
=================
Brief Summary
-----------------
Chronic inguinal neuralgia is one of the most important complications following inguinal hernia repair. It may even outweigh the benefit of the operation. Intraoperative neurectomy has been investigated to reduce the incidence of chronic pain. This study evaluates the effects of elective division of the ilioinguinal, iliohypogastric and genital branch of the genitofemoral nerves on pain and postoperative sensory symptoms after Lichtenstein hernia repair.

Official Title
-----------------
Effect of Elective Intraoperative Neurectomy on Chronic Pain After Lichtenstein Hernia Repair. A Prospective, Single-blind, Randomized, Controlled Clinical Trial

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Procedure: Lichtenstein hernia repair
* Procedure: Neurectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Uni- or bilateral inguinal hernia Karnofsky-index ≥70 Informed consent Exclusion Criteria: Recurrent inguinal hernia Previous inguinal operation Emergent operation Severe comorbidities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Neurectomy<br> | Procedure: Lichtenstein hernia repair<br>* Lichtenstein hernia repair with tension free mesh<br>Procedure: Neurectomy<br>* Neurectomy<br>|
| Other: Nerve preservation<br> | Procedure: Lichtenstein hernia repair<br>* Lichtenstein hernia repair with tension free mesh<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of postoperative pain |  | up to three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of hypesthesia or paraesthesia |  | one and three years | 
| Recurrence rate |  | one and three years | 
| Rate of intra- and postoperative complications |  | one and three years | 
| Quality of life |  | one and three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
inguinal hernia, chronic pain, neurectomy, hypesthesia
Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Study Overview
=================
Brief Summary
-----------------
Diarrhea-associated hemolytic uremic syndrome (D+HUS) is defined as a prodrome of enteritis followed by thrombocytopenia (< 150,000/mm3), microangiopathic hemolytic anemia, and signs of variable degrees of renal damage (increase in serum Cr, proteinuria, and/or hematuria) . Our aim is to detect the most reliable early predictors of poor prognosis to identify children at major risk of bad outcome who could eventually benefit from early specific treatments.

Detailed Description
-----------------
The disease is caused predominantly by Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC) and is one of the most common etiologies of acute kidney injury (AKI) and an important cause of acquired chronic kidney disease in children [2]. The incidence of HUC tends to parallel the seasonal fluctuation of E.coli o175 : H7 infection which peaks between June & September. Nowadays, the incidence increases and is typically observe in infants and children, especially those aged 6 months to 4 years. A complicated disease course is defined as the development of one or more of the following manifestations: neurological dysfunction, severe bowel injury, pancreatitis, hemodynamic instability (symptomatic hypotension, multi-organ failure), cardiac (congestive heart failure, myocarditis, pericarditis, arrhythmia) or pulmonary involvement (pulmonary edema, acute respiratory distress syndrome), hematologic complications (hemorrhage), and death [1]. Many laboratory and clinical markers upon admission have been associated to severe forms of the disease, including high initial leukocyte and hematocrit levels, major extrarenal complications, dehydration and recently, the blood urea nitrogen (BUN) to serum creatinine (Cr) ratio [1], [4-6]. Treatment of D+HUS remains supportive; thus, early identification of high-risk patients can optimize their management [1-3].

Official Title
-----------------
Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Conditions
-----------------
Hemolytic Uremic Syndrome of Childhood

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients less than 18 years diagnosed with Hemolytic Uremic Syndrome

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete remission | Number of cases that treated and discharged from hospital | 1 year | 
| Death | Number of cases that ended by death | 1 year | 
| Residual renal affection | Number of cases with residual raised renal chemistry | 1 year |
hsTnT in Patients Admitted to the ED With Atrial Fibrillation in the Era of NOACs - Heidelberg Registry of Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
The purpose of the Heidelberg Registry of Atrial Fibrillation (HERA-FIB) is to collect data on the prevalence and clinical significance of elevated cardiac troponin in a large registry of unselected patients with atrial fibrillation presenting to an emergency department in the era of novel oral anticoagulants (NOACs).

Official Title
-----------------
High-Sensitivity Cardiac Troponin T in Patients Admitted to the Emergency Department With Atrial Fibrillation in the Era of Novel Oral Anticoagulants - Heidelberg Registry of Atrial Fibrillation

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: documented atrial fibrillation availability of at least one hsTnT measurement Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular and non-vascular death |  | Follow up after at least 6 months | 
| Nonfatal myocardial infarction |  | Follow up after at least 6 months | 
| Stroke/systemic embolism |  | Follow up after at least 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stroke, systemic embolism, myocardial infarction, vascular death, non-vascular death, composite endpoint of vascular and non-vascular death, nonfatal MI, stroke/systemic embolism |  | Follow up after at least 6 months |
Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.

Detailed Description
-----------------
PROTOCOL OUTLINE: Patients are treated with daily olsalazine. The dose is increased each week until the protocol dose is reached. Supplemental acetaminophen is allowed; nonsteroidal anti-inflammatory drugs continue unchanged. Concurrent sulfasalazine is prohibited.

Conditions
-----------------
Ankylosing Spondylitis

Intervention / Treatment
-----------------
* Drug: olsalazine


Participation Criteria
=================
Eligibility Criteria
-----------------
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Meets modified New York diagnostic criteria Active disease, i.e., morning stiffness for more than 30 minutes Failed or experienced nonlife-threatening reaction to prior sulfasalazine No significant hematologic, hepatic, or renal disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: olsalazine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ankylosing spondylitis, genetic diseases and dysmorphic syndromes, rare disease
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Study Overview
=================
Brief Summary
-----------------
Natalizumab (TYSABRI) is a protein-based drug that is manufactured by Biogen Idec in partnership with Elan Pharmaceuticals. Natalizumab is approved in the US and Europe for the treatment of Multiple Sclerosis (MS). The purpose of this study is to determine whether the amount of natalizumab (TYSABRI) that is present in your blood (plasma) can be reduced or eliminated by separating and removing the plasma and replacing it with other fluids, a process called plasma exchange.

Official Title
-----------------
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

Conditions
-----------------
Relapsing Forms of Multiple Sclerosis

Intervention / Treatment
-----------------
* Procedure: Plasma exchange
* Drug: natalizumab treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: considered by the Investigator to be free of signs and symptoms suggestive of any serious opportunistic infection willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including interferon beta and glatiramer acetate) for the duration of the study willing and able to comply with the site's plasma exchange protocol which may require hospitalization or daily visits Exclusion Criteria: considered by the Investigator to be immunocompromised history of, or available abnormal laboratory results indicative of any major disease that would preclude the administration of a recombinant humanized antibody immunomodulating agent for the duration of the study. condition(s) considered to be contraindication(s) for plasma exchange, including but not limited to bleeding diathesis, hypotension, or vascular access limitations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Plasma exchange|nan|
|Drug: natalizumab treatment|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple sclerosis (MS)
Bedside Gastric Ultrasound for Assessment of ASA Preoperative Starving Guidelines Accuracy: Diabetic vs Non Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
To reduce the risk of perioperative pulmonary aspiration of gastric contents, oral intake of liquids or solids is not allowed for certain periods. Recently, the ultrasound (US) is used to evaluate the volume and the nature of the stomach content. In its latest recommendations, the American Society of Anesthesiologists (ASA) shortened the duration preoperative fasting. The aim of the study is to evaluate the efficacy of ASA recommendations in diabetic patients using ultrasound (US) scanning of the stomach (antrum).

Official Title
-----------------
Bedside Gastric Ultrasound for Assessment of ASA Preoperative Starving Guidelines Accuracy: Diabetic vs Non Diabetic Patients

Conditions
-----------------
Evaluation of ASA Fasting Recommendations in Diabetic Patients

Intervention / Treatment
-----------------
* Diagnostic Test: ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for elective orthopedic procedures. Exclusion Criteria: Patients with BMI > 35 kg.m-2, age <18y, ASA physical state >II, fasting more than 6hs, or with gastric diseases will be excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| D<br>diabetic patients | Diagnostic Test: ultrasound<br>* ultrasound examination of pyloric antrum<br>|
| ND<br>non-diabetic patients | Diagnostic Test: ultrasound<br>* ultrasound examination of pyloric antrum<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gastric volume |  | bedside test 5 minutes |